全文获取类型
收费全文 | 3123篇 |
免费 | 302篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 87篇 |
妇产科学 | 100篇 |
基础医学 | 388篇 |
口腔科学 | 34篇 |
临床医学 | 420篇 |
内科学 | 665篇 |
皮肤病学 | 37篇 |
神经病学 | 276篇 |
特种医学 | 69篇 |
外科学 | 249篇 |
综合类 | 56篇 |
一般理论 | 7篇 |
预防医学 | 628篇 |
眼科学 | 20篇 |
药学 | 167篇 |
中国医学 | 2篇 |
肿瘤学 | 205篇 |
出版年
2023年 | 46篇 |
2022年 | 47篇 |
2021年 | 93篇 |
2020年 | 79篇 |
2019年 | 104篇 |
2018年 | 99篇 |
2017年 | 91篇 |
2016年 | 85篇 |
2015年 | 77篇 |
2014年 | 105篇 |
2013年 | 187篇 |
2012年 | 253篇 |
2011年 | 225篇 |
2010年 | 156篇 |
2009年 | 92篇 |
2008年 | 198篇 |
2007年 | 178篇 |
2006年 | 174篇 |
2005年 | 193篇 |
2004年 | 161篇 |
2003年 | 155篇 |
2002年 | 130篇 |
2001年 | 26篇 |
2000年 | 21篇 |
1999年 | 17篇 |
1998年 | 37篇 |
1997年 | 20篇 |
1996年 | 20篇 |
1995年 | 16篇 |
1994年 | 16篇 |
1993年 | 16篇 |
1992年 | 13篇 |
1991年 | 10篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 9篇 |
1984年 | 8篇 |
1983年 | 12篇 |
1982年 | 12篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1976年 | 12篇 |
1975年 | 8篇 |
1965年 | 7篇 |
1964年 | 7篇 |
1963年 | 8篇 |
1962年 | 7篇 |
1959年 | 7篇 |
1934年 | 8篇 |
1927年 | 7篇 |
排序方式: 共有3432条查询结果,搜索用时 15 毫秒
31.
Oncogene SET Domain Bifurcated 1 (SETDB1)/ESET, an H3K9 methyltransferase, was originally discovered over two decades ago; however, its function in the immune response was not first reported until 2011. SETDB1 immune functions include B cell maturation, T cell activity regulation, and immune escape in cancer cells. In B lymphocytes, SETDB1 mediates the transition from pro-B to pre-B cells and represses endogenous retroviruses (ERV) to encourage B cell lineage differentiation and maturation. SETDB1 alters T cell function by methylating IL-2 and IL-17 promoters and mediating T cell lineage commitment and development. In addition, SETDB1 plays a critical role in ERV silencing within a variety of immune cells, which can indirectly weaken the immune response. Although SETDB1 is critical for normal immune cell function, overexpression in cancer cells negatively impacts immune cell fights against cancer through decreased tumour immunogenicity. Within cancer cells, SETDB1 overexpression represses production and infiltration of antitumour immune cells, mediates immune escape through TE and ERV silencing, represses the type I interferon pathway, and interferes in immune checkpoint blockade (ICB) outcomes by regulation of PD-L1 expression and IFN signalling. In this review, we further discuss the immunological mechanisms of SETDB1 in normal and cancerous cells and its implications in cancer immunotherapy. 相似文献
32.
Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes. 总被引:1,自引:0,他引:1
Eleanor S Segal Cecile Valette Laurence Oster Luc Bouley Catarina Edfjall Peter Herrmann Massimo Raineri Mary Kempff Saundra Beacham Cinda van Lierop 《Drug safety》2005,28(11):971-980
In view of the shortcomings of the current system for postmarketing drug surveillance that is based on voluntary spontaneous adverse drug reaction (ADR) reporting, new approaches are needed.We describe an approach involving a combination of limited distribution, patient and physician education, as well as a novel pharmaco-vigilance system that is capable of promoting the safe and adequate use of a new drug. Importantly, it provides the possibility of calculating true ADR occurrence rates, as the exposed population (denominator) and the number of patients with events (numerator) are known. These measures were taken for the oral dual endothelin ET(A)/ET(B) antagonist bosentan (Tracleer). In recent guidelines issued by the European Society of Cardiology, American College of Chest Physicians and the WHO, this drug is considered as first-line oral treatment for the treatment of pulmonary arterial hypertension, a devastating orphan disease associated with a poor prognosis. Bosentan was approved in 2001/2 on the basis of two pivotal studies that showed improved exercise capacity and haemodynamic parameters while delaying time to clinical worsening. Elevations in serum liver aminotransferase levels of >3 times the upper limit of normal were noted in 10.2% of patients (placebo-subtracted incidence). Therefore, liver function tests have to be performed on a regular basis. In addition, bosentan has potential as a teratogen.In the US, a controlled distribution network for bosentan (Tracleer) Access Program [T.A.P.]) and the development of a patient database to follow patients was set up. Accompanied by comprehensive physician and patient education programmes, T.A.P. was developed to provide a mechanism to assist with the primary risk management goals for bosentan therapy, namely pregnancy prevention and liver enzyme monitoring and prevention of hepatic injury.In Europe, the Tracleer) Excellence (TRAX PMS) database is a novel European non-interventional, prospective, internet-based surveillance system initiated by the manufacturer in cooperation with the European Medicines Agency. It collected potential safety signals associated with bosentan use including adverse events, elevations of liver aminotransferase levels, other abnormal laboratory values, death and hospitalisation. TRAX PMS has accrued 79% of all known patients in the EU and the data provide supportive 'real-life' evidence on the long-term safety of bosentan.The two different systems had similar goals and outcomes. The data received concerning thousands of patient-years of use have confirmed the clinical trial results regarding product safety and the favourable benefit/risk ratio of bosentan, especially with regard to known type A adverse events. The clinical monitoring algorithm has also been confirmed. In addition, no rare type B events were uncovered despite the increased reporting rate. These systems might serve as templates for future pharmaco-vigilance efforts regarding drugs that require particular safety attention. 相似文献
33.
Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). 总被引:5,自引:0,他引:5
Lindsay M Morton Patricia Hartge Theodore R Holford Elizabeth A Holly Brian C H Chiu Paolo Vineis Emanuele Stagnaro Eleanor V Willett Silvia Franceschi Carlo La Vecchia Ann Maree Hughes Wendy Cozen Scott Davis Richard K Severson Leslie Bernstein Susan T Mayne Fred R Dee James R Cerhan Tongzhang Zheng 《Cancer epidemiology, biomarkers & prevention》2005,14(4):925-933
BACKGROUND: The International Lymphoma Epidemiology Consortium (InterLymph) provides an opportunity to analyze the relationship between cigarette smoking and non-Hodgkin lymphoma with sufficient statistical power to consider non-Hodgkin lymphoma subtype. The results from previous studies of this relationship have been inconsistent, likely due to the small sample sizes that arose from stratification by disease subtype. To clarify the role of cigarette smoking in the etiology of non-Hodgkin lymphoma, we conducted a pooled analysis of original patient data from nine case-control studies of non-Hodgkin lymphoma conducted in the United States, Europe, and Australia. METHODS: Original data were obtained from each study and uniformly coded. Risk estimates from fixed-effects and two-stage random-effects models were compared to determine the impact of interstudy heterogeneity. Odds ratios (OR) and 95% confidence intervals (95% CI) were derived from unconditional logistic regression models, controlling for study center, age, sex, and race. RESULTS: In our pooled study population of 6,594 cases and 8,892 controls, smoking was associated with slightly increased risk estimates (OR, 1.07; 95% CI, 1.00-1.15). Stratification by non-Hodgkin lymphoma subtype revealed that the most consistent association between cigarette smoking and non-Hodgkin lymphoma was observed among follicular lymphomas (n = 1452). Compared with nonsmokers, current smokers had a higher OR for follicular lymphoma (1.31; 95% CI, 1.12-1.52) than former smokers (1.06; 95% CI, 0.93-1.22). Current heavy smoking (> or = 36 pack-years) was associated with a 45% increased OR for follicular lymphoma (1.45; 95% CI, 1.15-1.82) compared with nonsmokers. CONCLUSIONS: Cigarette smoking may increase the risk of developing follicular lymphoma but does not seem to affect risk of the other non-Hodgkin lymphoma subtypes we examined. Future research is needed to determine the biological mechanism responsible for our subtype-specific results. 相似文献
34.
35.
36.
Myrna F. Schwartz Ruth B. Fink Eleanor M. Saffran 《Neuropsychological rehabilitation》2013,23(1-2):93-127
Abstract Cognitive, or more specifically, psycholinguistic models of sentence processing disorders in agrammatism attempt to specify what types of mental computations (we call them linguistic skills) are affected, at what level of the model, and by what mechanism (e.g. retrieval failure, knowledge loss, capacity limitation). We outline a new, “modular treatments” approach to the rehabilitation of aphasia, using agrammatism as an example. This approach draws from the model-driven analysis an empirically and theoretically defensible enumeration of linguistic skills which are vulnerable to disruption in agrammatism. Specific interventions target each of the vulnerable skills, using designs that aim towards maximal generality in the affected population and that can be standardised for use in the clinic. Such targeted interventions are the “modules” of a complete rehabilitation programme. The clinician chooses which to administer and on what schedule, on a case-by-case basis. 相似文献
37.
38.
Winnie Wing-Yan Yuen Lynn Tran Carlos King-Ho Wong Eleanor Holroyd Catherine So-Kum Tang 《AIDS care》2016,28(7):816-824
Current HIV prevention interventions for female sex workers (FSWs) have tended to target the cognitive factors in changing their behaviors, yet little attention has been paid to the psychological factors that influence the behavior of women in sex work. This review aimed to explore the associations between the psychological health of FSWs and HIV risk. A total of eight studies published in English before July 2013 were identified and reviewed. FSWs had reported psychological issues, including depression, suicidal thoughts as well as lower quality of life, and the pooled prevalence of probable depression was as high as 62.4%. The majority of studies showed that higher scores in psychological health problems were associated with increased HIV risk behavior, in particular inconsistent condom use, or sexually transmitted infections. Among the five studies which measured symptoms of depression, four documented that higher depression scores were significantly associated with inconsistent condom use among FSWs with their clients and/or partners. Meta-analysis using a fixed-effects model was performed to examine the association between depression and inconsistent condom use and found that higher scores in depression were significantly associated with inconsistent condom use (odds ratio?=?2.57, p?.001). This review contends that future HIV preventive interventions should take psychological health of FSWs into consideration. 相似文献
39.
40.